Although there is ample evidence demonstrating that the TGF-β pathway is critical for the promotion of invasive mesenchymal properties of glioma cells [85–87, 197], studies have only recently started to dissect the molecular mechanisms through which TGF-β signaling drives the expression of EMT-related genes in GBM [174]. The gene discussed is TGFB1; the disease is central nervous system cancer.